



# HEP DART™ 2011

frontiers in drug development for viral hepatitis

DECEMBER 4-8, 2011

GRAND HYATT KAUI, KOLOA, HAWAII, USA

## Aloha!

We are pleased to announce HEP DART 2011, the 16th meeting in the DART series, which began in 1995. The Conference is open to anyone interested in therapies for viral hepatitis. The content of HEP DART 2011 was developed to primarily interest scientists and clinical researchers in the infectious diseases. The educational objectives of the meeting are as follows:

- Understand the role of viral targets in the drug development and discovery process
- Identify the next generation of inhibitors of viral hepatitis
- Assess the impact of resistance and treatment failure in the drug development and discovery process
- Increase awareness of the clinical impact of antiviral agents
- Understand the consequences of co-infection with HIV on the management of patients
- Assess the role of vaccines and therapeutic vaccines in future therapies for viral hepatitis

You will leave HEP DART 2011 with a renewed dedication to improve the lives of people living with hepatitis viruses. We look forward to your participation!

### HEP DART 2011 ORGANIZING COMMITTEE

**Raymond F. Schinazi**, *Emory University/Veterans Affairs Medical Center, USA* (Chair)

**Robert Murphy**, *Northwestern University, USA* (Chair)

**Charles Rice**, *The Rockefeller University, USA* (Co-chair)

**Eugene Schiff**, *University of Miami, USA* (Co-chair)

## PLENARY LECTURES

**Robert Purcell** (*National Institutes of Health, USA*)  
William H. Prusoff HEP DART Lifetime Achievement Award:  
The golden age of hepatitis research: A jaundiced view of history

**Palmer Beasley** (*University of Texas at Houston, USA*)  
Hepatitis viruses: Evolution and diversity

**Ralf Bartenschlager** (*University of Heidelberg, Germany*)  
Exploitation of host cell targets for HCV-specific therapy

**Charles Rice** (*The Rockefeller University, USA*)  
New *in vitro* and *in vivo* preclinical models for HCV drug discovery

**Michael Fried** (*University of North Carolina at Chapel Hill, USA*)  
IL28B - Impact on treatment decisions

**Stephen Locarnini** (*Victorian Infectious Diseases Reference Laboratory, Australia*)  
HBV and HCV antiviral drug resistance: Prevention and monitoring

**Marc Bourlière** (*Hôpital Saint Joseph, France*)  
The future of HCV therapy in non-genotype 1 patients

**Howard Thomas** (*Imperial College, UK*)  
HCV and the central nervous system

**Scott Friedman** (*Mount Sinai School of Medicine, USA*)  
Best targets for antifibrotic therapy

**Eugene Schiff** (*University of Miami, USA*)  
Turning despair into hope: Ripples becoming tsunamis

## IMPORTANT DATES

Conference dates - December 4-8, 2011

Early registration deadline - October 17, 2011

Abstract submission deadline - October 17, 2011

Abstract acceptance notification - October 24, 2011

Final date for online registration - November 30, 2011

Satellite Mini-symposium - 09:00 hours - December 4, 2011

Opening session - 15:00 hours - December 4, 2011

HEP DART 2011 Closes - 13:00 hours - December 8, 2011

## CONFIRMED SPEAKERS

### Global Burden of Hepatitis Viruses, Natural History and Management

**John Ward** (*Centers for Disease Control and Prevention, USA*)

**Steve Wiersma** (*WHO, Switzerland*)

**Janet Zola** (*San Francisco Department of Public Health, USA*)

### Discoveries and Advances in HCV Research

**Anna Lok** (*University of Michigan Medical Center, USA*)

**Alan Perelson** (*Los Alamos National Laboratory, USA*)

### New Targets: Cellular Systems and Infectious Models

**Pablo Gastaminza** (*Centro Nacional de Biotecnología-C.S.I.C., Spain*)

### Management of Hepatitis Infections and Genetic Markers

**Patrick Marcellin** (*Hôpital Beaujon, France*)

**David Thomas** (*Johns Hopkins University School of Medicine, USA*)

### Emergence, Re-emergence, Resistance, Prevention and Eradication of Hepatitis Viruses

**Massimo Levrero** (*Sapienza Università di Roma, Italy*)

**John Taylor** (*Fox Chase Cancer Center, USA*)

### Clinical Trial Design

**Jules Dienstag** (*Harvard Medical School, USA*)

**Douglas Dieterich** (*Mount Sinai School of Medicine, USA*)

**Paul Pockros** (*The Scripps Clinic, USA*)

### Review of Poster Presentations

**Adrian Di Bisceglie** (*Saint Louis University School of Medicine, USA*)

**Adrian Ray** (*Gilead Sciences, Inc., USA*)

### Debate: Are New Drugs Needed to Prevent HBV Adverse Outcomes or Treat HBV Infections?

**Tim Block** (*Moderator, Drexel Institute, USA*)

**Frank Chisari** (*Co-moderator, The Scripps Research Institute, USA*)

**Adrian DiBisceglie** (*Saint Louis University School of Medicine, USA*)

**Jules Dienstag** (*Harvard Medical School, USA*)

**Brian McMahon** (*Alaska Native Medical Center, USA*)

**David Thomas** (*Johns Hopkins University School of Medicine, USA*)

### Debate: HCV, HBV, HIV and Health Care Workers: A Debate on the Shea Guidelines

**Tracy Swan** (*Moderator, Treatment Action Group, USA*)

**Joan Block** (*Co-moderator, Hepatitis B Foundation, USA*)

**Jules Levin** (*NATAP, USA*)

**Anna Lok** (*University of Michigan Medical Center, USA*)

**David Thomas** (*Johns Hopkins University School of Medicine, USA*)

**John Ward** (*Centers for Disease Control and Prevention, USA*)

### New Targets: Insights into Drug Mechanisms

**Mariène Dreux** (*The Scripps Research Institute, USA*)

**Robert Lanford** (*Texas Biomedical Research Institute, USA*)

**Stanley Lemon** (*University of North Carolina at Chapel Hill, USA*)

**Adam Zlotnick** (*Indiana University, USA*)

### Pan Genotypic Therapies for Hepatitis Infections and Diagnosis

**Miriam Alter** (*University of Texas Medical Branch at Galveston, USA*)

**Mark Sulkowski** (*Johns Hopkins University, USA*)

### Co-infections, Therapeutic Modalities and Regulatory Issues: Dangerous Liaisons

**Marion Peters** (*University of California, San Francisco, USA*)

**Jürgen Rockstroh** (*University of Bonn, Germany*)

**Ken Sherman** (*University of Cincinnati College of Medicine, USA*)

### Immunological Approaches, Vaccines and Virus-host Interactions

**Frank Chisari** (*The Scripps Research Institute, USA*)

**T. Jake Liang** (*NIDDK, National Institutes of Health, USA*)

**Glenn Randall** (*The University of Chicago, USA*)

### Liver Damage: Decompensation, Fibrosis, Hepatocellular Carcinoma and Diagnostics

**Ira Jacobson** (*Weill Cornell Medical College, USA*)

**Brent Korba** (*Georgetown University, USA*)

**Masao Omata** (*University of Tokyo, Yamanashi Central Hospital, Japan*)

**Thierry Poynard** (*Groupe Hospitalier Pitié-Salpêtrière, France*)

### The Business of Antiviral Agents: Paying for Performance

**Abel De La Rosa** (*Moderator, Pharmasset, USA*)

**David Witzke** (*Co-moderator, PioneerPath Capital, USA*)

**Rachel McMinn** (*Bank of America Merrill Lynch, USA*)

**Geoffrey Meacham** (*JP Morgan Securities, Inc., USA*)

**Vivek Ramaswamy** (*QVT Financial LP, USA*)

**Frank Zavr1** (*Adage Capital, USA*)

## CURATIVE THERAPIES FOR HCV: RESISTANCE IS FUTILE A SATELLITE MINI-SYMPOSIUM

HEP DART attendees have a chance to hear from industry leaders about new developments in HCV therapeutics including combined modalities as well as their future plans. The mini-symposium is being held at **09:00** on **December 4, 2011** and is followed by a luncheon.



# HEP DART™ 2011

frontiers in drug development for viral hepatitis

## CONTINUING MEDICAL EDUCATION

### Accreditation Statement and Credit Designation Statement

Emory University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Emory University School of Medicine designates this educational activity for 27 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

## CONFERENCE VENUE

The Conference will be held **December 4-8, 2011** at the **Grand Hyatt Kauai**, 1571 Poipu Road, Koloa, Kauai, Hawaii, USA 96756



## ACCOMMODATION RATES

The Grand Hyatt is able to offer three (3) options of rooms to Conference delegates. The rates listed below are for single or double occupancy and do not include state and local taxes, which are currently 13.416%, and are subject to change without notice. A two-nights' deposit is required to guarantee the hotel reservation.

Garden/Mountain-View Room . . . . . Nightly rate: US \$190.00 + tax  
Partial Ocean-View Room . . . . . Nightly rate: US \$200.00 + tax  
Deluxe Ocean-View Room . . . . . Nightly rate: US \$255.00 + tax

Group rate as outlined above will be in effect from November 29, until December 13, 2011. Extensions prior to or past these dates are subject to room and rate availability. Delegates with accommodation requirements that are not provided for in the above list, i.e., suites, special access, etc. should contact the Conference Secretariat at +1 781 648 1933.

## REGISTRATION

Past HEP DART conferences were sold out events. The Organizing Committee strongly suggests that you register early to ensure your confirmation, as registration will close when the capacity of the venue is reached. Priority will be given to persons submitting an abstract. On-line registration is available on the Conference website at [www.HEPDART.com](http://www.HEPDART.com).

Payment of the Conference registration fee includes the following:

- Entrance into all scientific sessions, including poster area
- Delegate bag, including abstract book and final program
- Welcome reception following the Opening Session on Sunday, December 4, 2011
- Breakfasts on Monday-Thursday, December 5-8, 2011
- Refreshment breaks on Monday-Thursday, December 5-8, 2011
- Lunches (2)
- Poster Session Reception
- Closing Dinner

### Early Registration

Registration must be received on or before **Monday, October 17, 2011**; rates for registrations received after this date will be equal to the Early Registration rate +US \$150.

Conference registration fee . . . . . US \$800  
Academic/Government/Non-profit organization . . . . . US \$700  
Accompanying guests . . . . . US \$600

## CANCELLATION POLICIES

Please note that cancellation of registrations received or postmarked on or before **October 4, 2011** will incur a US \$75 administration fee. Cancellation of registrations received or postmarked after **October 4, 2011** and on or before **November 4, 2011** will incur a fee equivalent to 50% of the registration payment and 50% of the hotel deposit. No refund of the registration payment and hotel deposit will be issued for cancellations postmarked after **November 4, 2011**.

[www.HEPDART.com](http://www.HEPDART.com)

## ABSTRACT SUBMISSION

The Scientific Committee requests that authors submit their abstracts electronically via the Conference website at [WWW.HEPDART.COM](http://WWW.HEPDART.COM). For complete instructions regarding abstract submittal, please visit the Conference website. The abstract submission deadline is **October 17, 2011**.

For purposes of review and programming, abstracts are divided into topical categories. Selection of the most appropriate category is important as it determines who reviews your abstract. The Organizing Committee reserves the right to reassign your abstract to a more appropriate category.

- Advances in HCV and HBV Cell-based Assays and Animal Models
- Clinical Development of HBV/HCV Inhibitors
- Co-infection with HIV and Other Viruses
- Diagnostic Approaches and Non-invasive Markers
- Hepatocellular Carcinoma and Fibrosis
- Immunology and Vaccine Development
- Therapeutic Approaches, Combinations, Pharmacology, and Emerging Targets
- Next Generation of Anti-hepatitis Inhibitors
- Optimizing Outcome of Therapeutics for HBV/HCV
- Pathogenesis, Therapeutics, Viral Dynamics and Emerging Viruses
- Resistance to Antiviral Agents, Replication Fitness and Vaccine Escape Mutants
- Virus Persistence and Eradication Strategies

## SCHOLARSHIP FUND

There are a limited number of partial and/or travel scholarships for post-doctoral fellows, nurses, assistant professors, underrepresented minorities, patient advocates, and residents of developing countries. Preference will be given to those applicants who are submitting an abstract. Please contact the conference secretariat at [ajuodawlkis@informedhorizons.com](mailto:ajuodawlkis@informedhorizons.com) or +1 781 648 1933 for more information.

## HEP DART 2011 SUPPORTERS

The Organizing Committee would like to offer very special thanks to the following companies and organizations for their generous educational grants.

### PLATINUM SUPPORT



### GOLD SUPPORT




### SILVER SUPPORT



### BRONZE SUPPORT



### ADDITIONAL SUPPORT



**Raymond F. Schinazi & Family Foundation**

## CONFERENCE SECRETARIAT



1860 Montreal Road, Suite 2, Tucker, GA 30084 USA  
Tel: +1 781 648 1933 • Fax: +1 866 534 6438  
[ajuodawlkis@informedhorizons.com](mailto:ajuodawlkis@informedhorizons.com)  
[www.informedhorizons.com](http://www.informedhorizons.com)